South Korea Neurological Biomarkers Market Size, Share, Trends and Forecast by Type, Application, End Use, and Region, 2026-2034

July 2026 | 118 pages | ID: S8A524645BC4EN
IMARC Group

Abstracts

The South Korea neurological biomarkers market size reached USD 211.1 Million in 2025. Looking forward, the market is expected to reach USD 525.9 Million by 2034, exhibiting a growth rate (CAGR) of 10.35% during 2026-2034. The market is witnessing steady growth due to the rising prevalence of neurological disorders, advancements in diagnostic technologies, and increasing research in personalized medicine. Expanding healthcare infrastructure and growing awareness about early disease detection are further contributing to the expansion of the South Korea neurological biomarkers market share.

SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET TRENDS:

Rising Prevalence of Neurological Disorders and Aging Population

The aging population in South Korea is contributing to a prevalent increase in neurological diseases like Alzheimer's, Parkinson's, and other mental disorders. With an increase in the size of the elderly population, there is increased desperation for early identification and adequate surveillance of the neurodegenerative diseases. Biomarkers in neurology are a significant contribution to discovering conditions in time to conduct specific interventions. As people have become more knowledgeable about the pivotal role of preventative medicine, the need to have high-end diagnostic equipment has become imminent. The government healthcare policies are also coming in line with academic research and are working on establishing a preference in neurological health, which will only increase the demand. This demographic-driven rise in neurological conditions has become a core factor propelling the South Korea neurological biomarkers market growth.

Advancement in Omics Technologies and AI-Based Diagnostics

The integration of advanced technologies such as genomics, proteomics, and metabolomics is significantly enhancing biomarker discovery in South Korea. These omics-based tools, when combined with artificial intelligence and machine learning, enable precise molecular profiling and early diagnosis of neurological diseases. AI algorithms improve diagnostic accuracy by analyzing complex datasets, identifying biomarker patterns, and predicting disease progression. This tech-driven transformation is also fostering the development of personalized treatment plans tailored to individual patient profiles. Increased investment in precision medicine by both government bodies and private firms is driving innovation across diagnostic platforms. As South Korea leads in digital health adoption, the synergy of omics and AI technologies is playing a pivotal role in accelerating market expansion for neurological biomarkers.

Growing Focus on Non-Invasive Diagnostics and R&D Investment

There is a growing preference in South Korea for non-invasive diagnostic methods in neurology, especially blood-based and imaging biomarkers, which offer greater convenience and patient compliance compared to traditional approaches like biopsies or spinal taps. These tools facilitate earlier diagnosis and improve monitoring throughout the treatment process. Simultaneously, significant public and private sector investments in research and development (R&D) are accelerating innovation in biomarker development. Academic institutions, biotech firms, and government agencies are collaborating to support clinical trials, enhance biomarker validation, and promote commercialization. This combined focus on innovation and patient-centered diagnostics is opening new opportunities across hospitals, research labs, and diagnostic centers, positioning non-invasive biomarkers as a cornerstone of the country’s evolving neurological healthcare landscape.

SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on type, application, and end use.

Type Insights:

• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers
• Imaging Biomarkers
• Others

The report has provided a detailed breakup and analysis of the market based on the type. This includes genomic biomarkers, proteomic biomarkers, metabolomic biomarkers, imaging biomarkers, and others.

Application Insights:

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorders
• Others

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes Alzheimer's disease, Parkinson's disease, multiple sclerosis, autism spectrum disorders, and others.

End Use Insights:

• Hospital Laboratories
• Clinical Diagnostic Centers
• Research Organizations
• Others

The report has provided a detailed breakup and analysis of the market based on the end use. This includes hospital laboratories, clinical diagnostic centers, research organizations, and others.

Regional Insights:

• Seoul Capital Area
• Yeongnam (Southeastern Region)
• Honam (Southwestern Region)
• Hoseo (Central Region)
• Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and others.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea neurological biomarkers market performed so far and how will it perform in the coming years?
What is the breakup of the South Korea neurological biomarkers market on the basis of type?
What is the breakup of the South Korea neurological biomarkers market on the basis of application?
What is the breakup of the South Korea neurological biomarkers market on the basis of end use?
What is the breakup of the South Korea neurological biomarkers market on the basis of region?
What are the various stages in the value chain of the South Korea neurological biomarkers market?
What are the key driving factors and challenges in the South Korea neurological biomarkers market?
What is the structure of the South Korea neurological biomarkers market and who are the key players?
What is the degree of competition in the South Korea neurological biomarkers market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET - INTRODUCTION

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET LANDSCAPE

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET - BREAKUP BY TYPE

6.1 Genomic Biomarkers
  6.1.1 Overview
  6.1.2 Historical and Current Market Trends (2020-2025)
  6.1.3 Market Forecast (2026-2034)
6.2 Proteomic Biomarkers
  6.2.1 Overview
  6.2.2 Historical and Current Market Trends (2020-2025)
  6.2.3 Market Forecast (2026-2034)
6.3 Metabolomic Biomarkers
  6.3.1 Overview
  6.3.2 Historical and Current Market Trends (2020-2025)
  6.3.3 Market Forecast (2026-2034)
6.4 Imaging Biomarkers
  6.4.1 Overview
  6.4.2 Historical and Current Market Trends (2020-2025)
  6.4.3 Market Forecast (2026-2034)
6.5 Others
  6.5.1 Historical and Current Market Trends (2020-2025)
  6.5.2 Market Forecast (2026-2034)

7 SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET - BREAKUP BY APPLICATION

7.1 Alzheimer's Disease
  7.1.1 Overview
  7.1.2 Historical and Current Market Trends (2020-2025)
  7.1.3 Market Forecast (2026-2034)
7.2 Parkinson's Disease
  7.2.1 Overview
  7.2.2 Historical and Current Market Trends (2020-2025)
  7.2.3 Market Forecast (2026-2034)
7.3 Multiple Sclerosis
  7.3.1 Overview
  7.3.2 Historical and Current Market Trends (2020-2025)
  7.3.3 Market Forecast (2026-2034)
7.4 Autism Spectrum Disorders
  7.4.1 Overview
  7.4.2 Historical and Current Market Trends (2020-2025)
  7.4.3 Market Forecast (2026-2034)
7.5 Others
  7.5.1 Historical and Current Market Trends (2020-2025)
  7.5.2 Market Forecast (2026-2034)

8 SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET - BREAKUP BY END USE

8.1 Hospital Laboratories
  8.1.1 Overview
  8.1.2 Historical and Current Market Trends (2020-2025)
  8.1.3 Market Forecast (2026-2034)
8.2 Clinical Diagnostic Centers
  8.2.1 Overview
  8.2.2 Historical and Current Market Trends (2020-2025)
  8.2.3 Market Forecast (2026-2034)
8.3 Research Organizations
  8.3.1 Overview
  8.3.2 Historical and Current Market Trends (2020-2025)
  8.3.3 Market Forecast (2026-2034)
8.4 Others
  8.4.1 Historical and Current Market Trends (2020-2025)
  8.4.2 Market Forecast (2026-2034)

9 SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET – BREAKUP BY REGION

9.1 Seoul Capital Area
  9.1.1 Overview
  9.1.2 Historical and Current Market Trends (2020-2025)
  9.1.3 Market Breakup by Type
  9.1.4 Market Breakup by Application
  9.1.5 Market Breakup by End Use
  9.1.6 Key Players
  9.1.7 Market Forecast (2026-2034)
9.2 Yeongnam (Southeastern Region)
  9.2.1 Overview
  9.2.2 Historical and Current Market Trends (2020-2025)
  9.2.3 Market Breakup by Type
  9.2.4 Market Breakup by Application
  9.2.5 Market Breakup by End Use
  9.2.6 Key Players
  9.2.7 Market Forecast (2026-2034)
9.3 Honam (Southwestern Region)
  9.3.1 Overview
  9.3.2 Historical and Current Market Trends (2020-2025)
  9.3.3 Market Breakup by Type
  9.3.4 Market Breakup by Application
  9.3.5 Market Breakup by End Use
  9.3.6 Key Players
  9.3.7 Market Forecast (2026-2034)
9.4 Hoseo (Central Region)
  9.4.1 Overview
  9.4.2 Historical and Current Market Trends (2020-2025)
  9.4.3 Market Breakup by Type
  9.4.4 Market Breakup by Application
  9.4.5 Market Breakup by End Use
  9.4.6 Key Players
  9.4.7 Market Forecast (2026-2034)
9.5 Others
  9.5.1 Historical and Current Market Trends (2020-2025)
  9.5.2 Market Forecast (2026-2034)

10 SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET – COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 PROFILES OF KEY PLAYERS

11.1 Company A
  11.1.1 Business Overview
  11.1.2 Products Offered
  11.1.3 Business Strategies
  11.1.4 SWOT Analysis
  11.1.5 Major News and Events
11.2 Company B
  11.2.1 Business Overview
  11.2.2 Products Offered
  11.2.3 Business Strategies
  11.2.4 SWOT Analysis
  11.2.5 Major News and Events
11.3 Company C
  11.3.1 Business Overview
  11.3.2 Products Offered
  11.3.3 Business Strategies
  11.3.4 SWOT Analysis
  11.3.5 Major News and Events
11.4 Company D
  11.4.1 Business Overview
  11.4.2 Products Offered
  11.4.3 Business Strategies
  11.4.4 SWOT Analysis
  11.4.5 Major News and Events
11.5 Company E
  11.5.1 Business Overview
  11.5.2 Products Offered
  11.5.3 Business Strategies
  11.5.4 SWOT Analysis
  11.5.5 Major News and Events

12 SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET - INDUSTRY ANALYSIS

12.1 Drivers, Restraints, and Opportunities
  12.1.1 Overview
  12.1.2 Drivers
  12.1.3 Restraints
  12.1.4 Opportunities
12.2 Porters Five Forces Analysis
  12.2.1 Overview
  12.2.2 Bargaining Power of Buyers
  12.2.3 Bargaining Power of Suppliers
  12.2.4 Degree of Competition
  12.2.5 Threat of New Entrants
  12.2.6 Threat of Substitutes
12.3 Value Chain Analysis

13 APPENDIX